Skip to main content

Table 3 Anti-hypertensive (anti-HTN) drugs distribution

From: Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients

Characteristic/Variable

Non-T2D group (n = 15)

T2D group (n = 10)

p-value

Total anti-HTN drugs*

3.3 ± 0.5 [3.1 - 3.6]

4.1 ± 0.7 [3.6 - 4.6]

0.02

Thiazide diuretic

100% (15)

100% (10)

-

Aldosterone receptor inhibitor

26.6% (4)

50% (5)

0.40

Angiotensin converting enzyme inhibitor

66.6% (10)

50% (5)

0.68

Angiotensin receptor blocker

40% (6)

70% (7)

0.23

Calcium channel blocker

86.6% (13)

100% (10)

0.50

Centrally acting anti-hypertensive drug

6.6% (1)

40% (4)

0.12

  1. The values are expressed as means ± standard deviation; [95% confidence interval]; (*) Statistical significance (p < 0.05). Non-T2D: non type 2 diabetes resistant hypertension; T2D: type 2 diabetes resistant hypertension.